Previous studies have demonstrated that greater accumulation of HER-2 specific NK-92 cells in a model of HER2+ breast cancer brain metastasis was achieved when cells were administered immediately prior to FUS+MBs BTB/BBB disruption 31. This evidence concerns the gene ERBB2 and breast cancer.